María José Cilleruelo Ortega

María José Cilleruelo Ortega

Auto-generated profile, based on publicly available information

María José Cilleruelo Ortega

Department of Virology, Central Laboratory for Public Health, Asunción, Paraguay

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2022 in Anales de Pediatría
Verified
Journal Article
Open access
FGFrancisco José Álvarez García
Francisco José Álvarez García
MOMaría José Cilleruelo Ortega
María José Cilleruelo Ortega
JAJavier Álvarez Aldeán
Javier Álvarez Aldeán
MGMaría Garcés-Sánchez
María Garcés-Sánchez
ELElisa Garrote Llanos
Elisa Garrote Llanos
PMPepe Serrano Marchuet
Pepe Serrano Marchuet

1 January 2021 in Anales de Pediatría
Verified
Journal Article
Open access
FGFrancisco José Álvarez García
Francisco José Álvarez García
MOMaría José Cilleruelo Ortega
María José Cilleruelo Ortega
JAJavier Álvarez Aldeán
Javier Álvarez Aldeán
MGMaría Garcés-Sánchez
María Garcés-Sánchez
NSNuria García Sánchez
Nuria García Sánchez
JRJesús Ruiz-Contreras
Jesús Ruiz-Contreras
The CAV-AEP annually publishes the immunisation schedule considered optimal for all children and adolescent resident in Spain, taking into account the available evidence. The 2+1 schedule is recommended (2, 4, and 11 months) with hexavalent vaccines (DTPa-VPI-Hib-HB) and with 13-valent pneumococcal conjugate.A 6-year booster is recommended, preferably with DTPa (if available), with a dose of polio for those who received 2+1 schemes, as well as vaccination with Tdpa in adolescents and in each pregnancy, preferably between 27 and 32 weeks. Rotavirus vaccine should be systematic for all infants. Meningococcal B vaccine, with a 2+1 schedule, should be included in routine calendar. In addition to the inclusion of the conjugated tetravalent meningococcal vaccine (MenACWY) at 12 years of age with catch up to 18 years, inclusive, the CAV recommends this vaccine to be also included at 12 months of age, replacing MenC. Likewise, it is recommended in those over 6 weeks of age with risk factors or who travel to countries with a high incidence of these serogroups. Two-dose schedules for triple viral (12 months and 3-4 years) and varicella (15 months and 3-4 years) will be used. The second dose could be applied as a tetraviral vaccine. Universal systematic vaccination against HPV is recommended, regardless of gender, preferably at 12 years, and greater effort should be made to improve coverage. The 9 genotype extends coverage for both genders.

15 September 2023 in Vaccine
Verified
Journal Article
Closed access
SISandra Irala
Sandra Irala
SHSarah Hamid
Sarah Hamid
EPElena Penayo
Elena Penayo
FMFabiana Michel
Fabiana Michel
PCPaula Couto
Paula Couto
FNFrancisco Nogareda
Francisco Nogareda

25 January 2022 in Quaderns de Psicologia
Verified
Journal Article
Open access
PDF file
CVCaterine Galaz Valderrama
Caterine Galaz Valderrama
PCPastor Cea
Pastor Cea
DMDaniela Molina
Daniela Molina
DCDaniela Castro
Daniela Castro
MOMaría José Ortega
María José Ortega
Chile ha diversificado su población migrante a partir de la llegada de personas de América Latina y, a pesar de no ser estadísticamente significativo, esto ha generado una proliferación de imaginarios sociales negativos, afianzados institucionalmente a través de enfoques restrictivos hacia colectivos extranjeros. El racismo institucional se plasma en políticas, discursos y prácticas, ubicando en posiciones de desigualdades a algunos grupos migrantes. A través de una investigación cualitativa llevada a cabo en la XI región de Aysén (Chile), y por medio de un análisis interseccional, presentamos las maneras en que se articulan desigualdades como la procedencia nacional, la clase y el género, en la atención en salud pública. Los resultados muestran la existencia de prácticas racistas institucionales e imaginarios de “otredad” que les subyacen; las formas en que opera un racismo institucional a partir de discriminaciones explícitas; y las agencias y resistencias llevadas a cabo por personas racializadas.

1 January 2018 in Anales de Pediatría (English Edition)
Verified
Journal Article
Open access
DMDavid MORENO Moreno
David MORENO Moreno
FGFrancisco José Álvarez García
Francisco José Álvarez García
JAJavier Álvarez Aldeán
Javier Álvarez Aldeán
MOMaría José Cilleruelo Ortega
María José Cilleruelo Ortega
MSMaría Garcés Sánchez
María Garcés Sánchez
JRJesús Ruiz-Contreras
Jesús Ruiz-Contreras
The Advisory Committee on Vaccines of the Spanish Association of Paediatrics annually publishes the immunisation schedule considered optimal for children resident in Spain, according to available evidence on current vaccines. Regarding funded immunisations, 2 + 1 strategy (2, 4, 11–12 months) with hexavalent (DTPa-IPV-Hib-HB) and 13-valent pneumococcal vaccines are recommended. Administration of the 6-year booster dose with DTPa is recommended, and a poliomyelitis dose for children who had received the 2 + 1 scheme, as well as Tdap vaccine for adolescents and pregnant women in every pregnancy between 27 and 32 weeks’ gestation. The two-dose scheme should be used for MMR (12 months and 2–4 years) and varicella (15 months and 2–4 years). MMRV vaccine could be applied as the second dose if available. Coverage of human papillomavirus vaccination in girls aged 12 with a two dose scheme (0, 6 months) should be improved. Information and recommendation for male adolescents about potential beneficial effects of this immunisation should be provided as well. The new 9 genotypes vaccine is now available, expanding the coverage for both gender. Regarding non-funded immunisations, Committee on Vaccines of the Spanish Association of Paediatrics recommends meningococcal B vaccination, with a 3 + 1 schedule, and requests to be included in the National Immunisation Program. Tetravalent meningococcal vaccine (MenACWY) is recommended to adolescents (14–18 years) who are going to live in countries with systematic vaccination against ACWY serogroups, and people >6 weeks of age with risk factors or travellers to countries with very high incidence. Vaccination against rotavirus is recommended in all infants. El Comité Asesor de Vacunas de la Asociación Española de Pediatría publica anualmente el calendario de vacunaciones que estima idóneo para los niños residentes en España, teniendo en cuenta la evidencia disponible. En cuanto a las vacunas financiadas, se recomienda emplear el esquema 2+1 (2, 4 y 11-12 meses) con vacunas hexavalentes (DTPa-VPI-Hib-VHB) y con antineumocócica conjugada 13-valente. Se aconseja un refuerzo a los 6 años, preferentemente con DTPa, junto a una dosis de polio para aquellos que recibieron esquemas 2+1, así como vacunación con Tdpa en adolescentes y en cada embarazo, entre la 27 y 32 semanas. Se emplearán esquemas de dos dosis para triple vírica (12 meses y 2-4 años) y varicela (15 meses y 2-4 años). De haber disponibilidad, la segunda dosis se podría aplicar como vacuna tetravírica. Se deben incrementar las coberturas frente al papilomavirus en niñas de 12 años con dos dosis (0, 6 meses), así como informar y recomendar la vacunación de los varones, dados los beneficios potenciales de la misma. La nueva vacuna de 9 genotipos ya está disponible, ampliando la cobertura para ambos sexos. Respecto a vacunas no financiadas, se recomienda la antimeningocócica B, con esquema 3+1, solicitando su entrada en calendario. Se recomienda individualmente la vacuna antimeningocócica conjugada tetravalente (MenACWY) en adolescentes (14-18 años) que vayan a residir en países con vacunación sistemática frente a los serogrupos ACWY. También en mayores de 6 semanas de vida con factores de riesgo o viajeros a países de elevada incidencia. Es recomendable vacunar a todos los lactantes frente al rotavirus.

1 August 2014 in Anales de Pediatría
Verified
Journal Article
Closed access
RPR. Piñeiro Pérez
R. Piñeiro Pérez
CCC. de Lucas Collantes
C. de Lucas Collantes
FBFernando Baquero-Artigao
Fernando Baquero-Artigao
CCC. Fernández Camblor
C. Fernández Camblor
MOM.J. Cilleruelo Ortega
M.J. Cilleruelo Ortega